News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Sunandana Chandra, MD, Northwestern Medicine

Articles by Sunandana Chandra, MD, Northwestern Medicine

Treatment Optimization for Patients With Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Future Treatment Landscape for Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Promising Late-Stage Trials in Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Novel Approaches for Relapsed/Refractory Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Management of Brain Metastases in Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

I/O Dosing Schedules in Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Novel Therapies for Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Systemic Therapy for Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Therapy for Melanoma: Safety and Efficacy

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Data Explored for Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Neoadjuvant Data Explored for Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

pCR and Neoadjuvant Therapy for Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Molecular Testing in Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Identifying Patients for Neoadjuvant Melanoma Therapy

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Optimal Management of Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Latest Updated Articles

Identifying Patients for Neoadjuvant Melanoma Therapy
Published: June 23rd 2020 | Updated:
Systemic Therapy for Metastatic Melanoma
Published: June 23rd 2020 | Updated:
Molecular Testing in Locally Advanced Melanoma
Published: June 23rd 2020 | Updated:
Optimal Management of Locally Advanced Melanoma
Published: June 23rd 2020 | Updated:
$Novel Approaches for Relapsed/Refractory Melanoma$
Novel Approaches for Relapsed/Refractory Melanoma
Published: June 23rd 2020 | Updated:
Novel Therapies for Metastatic Melanoma
Published: June 23rd 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma